Collectionner le produit
Détails du produit
Synonyms
IGF-I, IGF1A, somatomedin C, MGF
Source
Human IGF-I Protein, Fc Tag (IG1-H5263) is expressed from human 293 cells (HEK293). It contains AA Gly 49 - Ala 118 (Accession # P05019-1).
Predicted N-terminus: Phe
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the N-terminus.
The protein has a calculated MW of 34.1 kDa. The protein migrates as 38-40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Human IGF-I Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human IGF-I Protein, Fc Tag (Cat. No. IG1-H5263) is more than 95% and the molecular weight of this protein is around 68-82 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human IGF-I Protein, Fc Tag (Cat. No. IG1-H5263) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IGFBP-4 Protein, His,Avitag (Cat. No. IG4-H82E3) with a linear range of 0.005-0.078 μg/mL (QC tested).
Protocol
Immobilized Human IGFBP-3, His Tag (Cat. No. IG3-H52H9) at 5 μg/mL (100 μL/well) can bind Human IGF-I Protein, Fc Tag (Cat. No. IG1-H5263) with a linear range of 0.3-5 ng/mL (Routinely tested).
Protocol
Immobilized Human IGF-I R, His Tag (Cat. No. IGR-H5229) at 5 μg/mL (100 μL/well) can bind Human IGF-I Protein, Fc Tag (Cat. No. IG1-H5263) with a linear range of 0.01-0.156 μg/mL (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Insulin-like growth factor I
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
9 Détails
- Étape de développement la plus élevée：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
